Molecular Partners Advances Radio-DARPin Pipeline with Phase 1/2a Trial Progress
Event summary
- Phase 1/2a trial of MP0712, a DLL3-targeted Radio-DARPin co-developed with Orano Med, is ongoing with initial data expected within months and comprehensive efficacy data in 2027.
- Compassionate care program initiated by NuMeRI in South Africa using 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope-agnostic vectors.
- First-in-human imaging for MP0726, targeting mesothelin (MSLN), planned to start in H2 2026.
- New target nomination expected in H2 2026, with two INDs planned in 2027.
The big picture
Molecular Partners is advancing its pipeline of targeted alpha radiotherapeutics, leveraging DARPins' versatility to address unmet needs in oncology. The progress in Phase 1/2a trials and the initiation of compassionate care programs highlight the company's strategic focus on expanding its radiopharmaceutical portfolio. This aligns with broader industry trends towards precision medicine and targeted cancer therapies, positioning Molecular Partners as a key player in the evolving radiopharmaceutical landscape.
What we're watching
- Clinical Data Timing
- The pace at which initial and comprehensive data from the MP0712 Phase 1/2a trial will influence investor confidence and strategic partnerships.
- Pipeline Versatility
- Whether Molecular Partners can sustain its isotope-agnostic approach across multiple targets and indications, enhancing its competitive edge.
- Regulatory Pathways
- How the compassionate care program in South Africa will impact regulatory strategies for MP0712 and future Radio-DARPin candidates.
Related topics